🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

39 results for “TG THERAPEUTICS, INC.” Clear

  1. DIPHENHYDRAMINE, METHYLPREDNISOLONE, PARACETAMOL, ublituximab, Ublituximab, ublituximab, CETIRIZINE, DEXAMETHASONE

    TG THERAPEUTICS, INC.

    Relapsing multiple sclerosis, Myasthenia Gravis

    phase 1 small molecule active

    1 trial

  2. NM1F Injection

    TG THERAPEUTICS, INC.

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  3. TG-1701

    TG THERAPEUTICS, INC.

    Non Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial

  4. TG-1801

    TG THERAPEUTICS, INC.

    CLL

    phase 1 mab terminated

    1 trial

  5. TG-1801

    TG THERAPEUTICS, INC.

    B-Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  6. TGI-5

    TG THERAPEUTICS, INC.

    CRC (Colorectal Cancer)

    phase 1 small molecule active

    1 trial

  7. TGI-6 Injection

    TG THERAPEUTICS, INC.

    Advanced or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

  8. TGR-1202

    TG THERAPEUTICS, INC.

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  9. TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 1 small molecule completed

    1 trial

  10. TGR-1202

    TG THERAPEUTICS, INC.

    Non-Hodgkin's Lymphoma

    phase 1 small molecule completed

    1 trial

  11. TGR-1202 + Obinutuzumab + Chlorambucil

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  12. TGR-1202 + brentuximab vedotin

    TG THERAPEUTICS, INC.

    Hodgkin's Lymphoma

    phase 1 small molecule completed

    1 trial

  13. Ublituximab + TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  14. Ublituximab

    TG THERAPEUTICS, INC.

    Multiple Sclerosis

    approved mab active

    4 trials

  15. Ublituximab

    TG THERAPEUTICS, INC.

    Multiple Sclerosis (MS) - Relapsing-remitting

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources